US Patent 9028830 Antibodies to CD122
All edits
Edits on 30 May, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 3 Dec, 2023
Golden AI
Edits made to:
Article (+452 characters)
Article
Patent abstract
The invention provides monoclonal antibodies that specifically bind to CD122, which is one component of receptors for IL-2 and IL-15. The monoclonal antibodies have the capacity for substantial inhibition of both IL-2 and IL-15 mediated functions by inhibiting binding of these cytokines to their receptors. The monoclonal antibodies can be used for inhibiting undesired immune responses or treatment of cancer, among other applications.
Edits on 27 Sep, 2023
Golden AI
Edits made to:
Infobox (+4 properties)
Infobox
Patent Inventor Names
J. Yun Tso0
Naoya Tsurushita0
Nicholas F. Landolfi0
Shankar Kumar0
Edits on 14 Jul, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 09028830 Antibodies to CD122 US Patent 9028830 Antibodies to CD122
Infobox
Patent Number
09028830
Patent Number
9028830
Edits on 19 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 8 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 30 Dec, 2021
Golden AI
Edits made to:
Infobox (+7 properties)
US Patent 09028830 Antibodies to CD122
Infobox
Is a
Patent jurisdiction
Patent number
09028830
Date of patent
May 12, 2015
Patent application number
13082352
Date Filed
April 7, 2011
Patent primary examiner
Find more entities like US Patent 9028830 Antibodies to CD122
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
